Singapore: Mesh Bio, a Singaporean health-tech startup, has raised US$1.8 million in a seed funding round, led by deep-tech investor Elev8.vc and SEEDS capital.
Wealth management firm Citrine Capital as well as Singaporean VC firm Tael Partners also joined the round.
Mesh Bio intends to use the capital to accelerate the rollout of its solution, DARA, for healthcare providers in Southeast Asia and Hong Kong. The funds will also support the startup’s clinical partnerships and collaborations.
The two-year-old company was started by Andrew Wu (former COO of Clearbridge Biomedics) Arsen Batagov ( former bioinformatics scientist) and Melvin Heng ( physician and hospital administrator) when they noticed the rise in chronic diseases, making patient management increasingly complex and challenging.
Their solution helps specialists, general practitioners, and doctors lacking specialist training in endocrinology predict diseases before it even occurs.
Furthermore, it also manages challenging patient cases by drawing in-patient data and translating it into actionable insight.